Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating today. Marc Frahm has given his Buy rating due to a combination of factors including promising trial ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target was raised to $40.00. Andres Y. Maldonado ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

(The Center Square) – Texans on Tuesday resoundingly reelected U.S. Sen. Ted Cruz and handed the state's 40 Electoral College votes to former President Donald Trump, both Republicans who previously ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 28.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 748,489 shares ...

As of 11:10 a.m. EDT. Market Open. CAMBRIDGE, Mass., October 31, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...